{"nctId":"NCT00945906","briefTitle":"An Open Enrollment Study of Factor XIII Concentrate in Subjects With Congenital Factor XIII Deficiency","startDateStruct":{"date":"2009-09"},"conditions":["Factor XIII Deficiency"],"count":61,"armGroups":[{"label":"FXIII","type":"EXPERIMENTAL","interventionNames":["Biological: FXIII Concentrate (Human) (FXIII)"]}],"interventions":[{"name":"FXIII Concentrate (Human) (FXIII)","otherNames":["Fibrogammin-P®","Corifact®"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Written informed consent/assent for study participation obtained before undergoing any study specific procedures\n* Diagnosed with congenital FXIII deficiency requiring prophylactic treatment\n* Males and females of any age\n\nExclusion Criteria:\n\n* Diagnosis of acquired FXIII deficiency\n* Administration of a FXIII-containing product, including blood transfusions or other blood products, within 3 weeks prior to the Baseline/Day 0 Visit\n* Any known congenital or acquired coagulation disorder other than congenital FXIII deficiency\n* Use of any other IMP within 4 weeks prior to Baseline/Day 0 Visit\n* Female subjects of childbearing potential not using, or not willing to use, a medically reliable method of contraception for the entire duration of the study\n* Suspected inability (e.g., language problems) or unwillingness to comply with study procedures or history of noncompliance\n* Any laboratory finding or medical condition which, in the opinion of the Investigator, would put the subject or subject's disease management at risk","healthyVolunteers":false,"sex":"ALL","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Adverse Events","description":"Number of subjects with any treatment-emergent adverse event (AE), treatment-related AE or serious AE (SAE). Treatment-related AEs are defined as AEs whose relationship to treatment is related, or possibly related and AEs with missing relationship.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"42","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null}]}]}]},{"type":"SECONDARY","title":"Hematology and Chemistry Testing","description":"Number of participants with treatment-emergent clinically significant hematology and/or chemistry laboratory parameter values.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"FXIII Antibody Testing","description":"Number of participants with serum Factor XIII antibodies.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"60","spread":null}]}]}]},{"type":"SECONDARY","title":"FXIII Concentration","description":"Trough Factor XIII concentration.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0987","spread":"0.03695"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.1177","spread":"0.03484"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.1238","spread":"0.02973"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.1075","spread":"0.03196"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.1025","spread":"0.04573"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.1160","spread":"0.03578"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.1341","spread":"0.03346"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.1667","spread":"0.06658"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0950","spread":"0.02121"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.1083","spread":"0.07489"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0933","spread":"0.04509"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0500","spread":"0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.1246","spread":"0.02961"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.1400","spread":"0.01414"}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With at Least One Bleeding Episode","description":"Number of subjects with at least one bleeding episode at any time after the first infusion in the study, and the number of subjects with at least one bleeding episode requiring Factor XIII treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Bleeding Episodes","description":"Number of bleeding episodes at any time after the first infusion in the study.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":2,"n":61},"commonTop":["Fever","Cough","Upper respiratory infection","Bruising","Headache"]}}}